In Vitro Efficacy Testing Services for Constipation

We provide robust and sensitive in vitro screening and characterization platforms for accelerating the discovery and screening of potential therapies for Constipation. Our services enable precise evaluation of drug candidates targeting the key pathways involved in gastrointestinal motility, secretion, and neurotransmission. We focus on receptors and proteins such as opioid receptors, serotonin receptors, muscarinic receptors, and components of the enteric nervous system, all of which are implicated in the pathophysiology of constipation. Our assays assess mechanisms related to impaired motility, secretion, and neural regulation, enabling comprehensive investigation of potential therapeutics.

Our portfolio includes a diverse range of biochemical, cell-based, radioligand binding, and functional assays to evaluate compound efficacy, potency, and mechanism of action. These methods facilitate the identification of modulators of gastrointestinal targets, assessment of receptor binding, signaling pathways, and functional outcomes relevant to constipation. The combination of these approaches ensures thorough characterization of new drug candidates.

Acetylthiocholine as substrate: Used in cholinesterase activity assays to evaluate compounds that modulate cholinergic signaling affecting gut motility.

Arrestin protease recruitment assay: Assesses GPCR activation and desensitization, relevant for drugs targeting receptor-mediated motility regulation.

Bioluminescence resonance energy transfer (BRET) assay: Measures real-time protein-protein interactions or second messenger responses, useful for studying GPCR signaling.

Charcoal meal test: A functional assay to assess gastrointestinal transit by measuring charcoal progression, indicating changes in motility.

Chemiluminescent assay: Quantifies molecular or cellular events using luminescence, enabling detection of signaling pathway activation.

Competitive binding assay: Determines compound affinity for receptors by measuring displacement of labeled ligands, critical for target validation.

Displacement of radiolabeled ligands (e.g., [125I], [3H], europium-DTPA): Measures binding affinities and receptor selectivity by quantifying competition for receptor binding sites.

Dye assay: Detects cellular or enzymatic activity via colorimetric changes, applicable for broad functional screening.

ELISA assay: Quantifies specific proteins or signaling molecules, enabling detection of molecular changes relevant to constipation mechanisms.

Electrical threshold test: Evaluates neuronal or muscle excitability, useful for assessing neuromuscular responses in gut tissues.

Fecal pellets output: Measures changes in stool output in organ culture or ex vivo systems, directly assessing prokinetic or laxative effects.

Fluorescence resonance energy transfer (FRET) assay: Monitors dynamic protein interactions or signal transduction events with high sensitivity.

Fluorescent (Aequorin) assay: Assesses intracellular calcium flux, relevant for studying smooth muscle contraction and neurotransmitter release.

Gene reporter assay: Detects activation of specific signaling pathways via reporter gene expression, indicating pathway modulation.

Homogeneous Time Resolved Fluorescence (HTRF) assay: Quantifies molecular interactions or second messenger levels using time-resolved fluorescence.

Hot-plate, tail immersion, and tail-flick tests: Functional assays primarily for nociceptive responses, but can indicate opioid receptor engagement relevant to constipation side effects.

Luciferin/luciferase and Nano-luciferin/luciferase assay: Highly sensitive detection of gene expression or ATP levels, reflecting cellular activity.

Occupancy assay: Measures the proportion of target receptors occupied by a compound, informing on drug-target engagement.

RNA assay: Quantifies gene expression changes in response to treatments, elucidating molecular mechanisms.

Radioactivity assay: Measures labeled compound uptake or binding, providing quantitative pharmacological data.

Saturation binding assay: Determines receptor density and ligand affinity, essential for understanding drug-receptor interactions.

Surface plasmon resonance assay: Real-time measurement of binding kinetics and affinities between biomolecules.

Taurocholate uptake assay: Assesses bile acid transport, relevant for evaluating secretory processes in the gut.

Voltage-clamp and whole-cell patch-clamp assays: Measure ion channel activity and membrane potentials, important for studying neuromuscular transmission.

[35S]-GTPgammaS binding assay: Measures G protein activation downstream of GPCRs, indicating functional receptor responses.

beta-Galactosidase assay: Reporter assay for gene expression, useful for pathway analysis.

cAMP accumulation assay: Quantifies intracellular cAMP, reflecting GPCR or other signaling pathway activation.

cGMP production assay: Measures cGMP levels, relevant for drugs modulating smooth muscle relaxation.

We measure a comprehensive set of pharmacological parameters to characterize compound potency, efficacy, binding affinity, and functional activity. These parameters are critical for comparing candidate drugs, optimizing their profiles, and guiding preclinical development. By providing quantitative benchmarks such as EC-50, IC-50, Ki, and others, we facilitate informed decision-making in the drug discovery process.

EC-50: The concentration of a drug that produces 50% of its maximal effect, indicating compound potency.

ED-50: The dose required to achieve 50% of the maximal response in a biological system, important for dose-response assessments.

IC-50: The concentration of an inhibitor where the response (or binding) is reduced by half, used to compare inhibitory strengths.

Kb: The equilibrium dissociation constant for an antagonist, reflecting binding strength at the receptor.

Kd: The equilibrium dissociation constant for ligand-receptor binding, a fundamental measure of affinity.

Ki: The inhibition constant, representing compound affinity in competitive binding assays.

MEC: Minimum effective concentration, the lowest concentration at which a compound exerts a measurable effect.

MED: Minimum effective dose, the smallest dose producing a desired pharmacological effect.

MIC: Minimum inhibitory concentration, the lowest concentration that inhibits a specific biological function.

pA-2: Negative logarithm of the antagonist concentration needed to double the agonist concentration for the same response, used for antagonist potency.

pEC-50: Negative logarithm of the EC-50 value, commonly used to express potency on a log scale.

pIC-50: Negative logarithm of the IC-50 value, providing a log-scale measure of inhibitor potency.

pKb: Negative logarithm of Kb, a log-scale measure of antagonist binding affinity.

pKd: Negative logarithm of Kd, a log-scale measure of binding affinity.

pKi: Negative logarithm of Ki, a widely used index of binding affinity in pharmacology.

Recommended In Vitro Efficacy Tests

5-Hydroxytryptamine Receptor 4

The 5-Hydroxytryptamine Receptor 4 (5-HT4) modulates gastrointestinal motility and is a key target in constipation drug development. Testing 5-HT4 activity is critical to assess efficacy and safety of candidate compounds. We offer assays—including cAMP accumulation, luciferin/luciferase, [³H]-serotonin/GR-113808 displacement, [³⁵S]-GTPγS binding, HTRF, occupancy, fluorescent, and gene reporter assays—to determine key pharmacological parameters: ED₅₀, EC₅₀, IC₅₀, pEC₅₀, pIC₅₀, Ki, pKi, and pKd.

Acetylcholinesterase (Yt Blood Group)

Acetylcholinesterase (Yt Blood Group) modulates cholinergic signaling, impacting gut motility and thus constipation. Testing its activity is vital in constipation drug development to assess compound efficacy and safety. Using acetylthiocholine as a substrate, this assay determines inhibitory potency (IC-50) and binding affinity (Ki), providing key pharmacological parameters for candidate drugs targeting acetylcholinesterase-mediated pathways.

Chloride Voltage-Gated Channel 2

Chloride Voltage-Gated Channel 2 (ClC-2) regulates intestinal fluid secretion, making it a key target in constipation drug development. Testing ClC-2 function is crucial for evaluating drug efficacy and safety. Our service employs voltage-clamp and whole-cell patch-clamp assays at relevant voltages (-120 mV, -30 mV) to measure channel activity. Main parameters assessed include MEC (minimum effective concentration), EC-50 (half-maximal effective concentration), and IC-50 (half-maximal inhibitory concentration).

Cholecystokinin A Receptor

Cholecystokinin A Receptor (CCK-AR) modulates gastrointestinal motility, making it a key target in constipation drug development. Testing CCK-AR involves ligand displacement assays using radiolabeled compounds such as [125I]-Bolton-Hunter sulfated CCK octapeptide, [3H]-L-364718, and [3H]-CCK octapeptide. These assays determine drug-receptor interactions, providing critical parameters—ED-50, IC-50, pA-2, Ki, and pKi—to assess compound potency and efficacy, guiding therapeutic candidate selection.

Cholinergic Receptor Muscarinic 1

The Cholinergic Receptor Muscarinic 1 (CHRM1) modulates gastrointestinal motility, making it a key target in constipation drug development. Accurate CHRM1 testing is essential to evaluate drug efficacy and selectivity. We utilize HTRF, [3H]-pirenzepine and [3H]-N-methylscopolamine displacement, and fluorescent assays to assess ligand binding and functional response. Main parameters reported include EC-50, pEC-50 (potency), and Ki, pKi (binding affinity), ensuring robust characterization of candidate compounds.

Diacylglycerol O-Acyltransferase 1

Diacylglycerol O-Acyltransferase 1 (DGAT1) modulates intestinal lipid metabolism, influencing gut motility and constipation. DGAT1 inhibition is a promising target for constipation drug development. Our DGAT1 testing service employs a sensitive radioactivity assay to quantify enzyme activity and determine IC50 values for candidate compounds, enabling precise assessment of inhibitory potency. This testing is crucial for identifying effective DGAT1 inhibitors and optimizing drug candidates for constipation therapy.

Growth Hormone Secretagogue Receptor

Growth Hormone Secretagogue Receptor (GHSR) modulates gastrointestinal motility, making it a promising target in constipation drug development. Our GHSR testing service utilizes [35S]-GTPγS binding, FRET, and fluorescent assays to evaluate compound activity. Critical parameters such as EC-50, IC-50, and pEC-50 are determined, providing essential data on potency and efficacy, and supporting the selection and optimization of novel constipation therapeutics.

Guanylate Cyclase 2C

Guanylate Cyclase 2C (GC-C) regulates intestinal fluid secretion; its activation alleviates constipation. GC-C testing is crucial for developing constipation drugs targeting this pathway. Key methods include cGMP production assays and dye assays to assess receptor activation. Main parameters measured are Minimum Effective Dose (MED), Effective Dose 50 (ED-50), and Effective Concentration 50 (EC-50) to determine drug potency and efficacy.

Mucin 5Ac, Oligomeric Mucus/Gel-Forming

Mucin 5Ac, Oligomeric Mucus/Gel-Forming, is crucial for intestinal mucus viscosity and barrier function, both of which are often altered in constipation. Our testing service evaluates Mucin 5Ac expression and secretion using ELISA and RNA assays, providing quantitative insights for constipation drug development. Key parameters such as MIC (minimum inhibitory concentration) are assessed to determine compound efficacy in modulating Mucin 5Ac, supporting targeted therapeutic strategies.

Opioid Receptor Kappa 1

Opioid Receptor Kappa 1 (KOR-1) plays a key role in modulating gastrointestinal motility, making it vital in constipation drug development. Testing KOR-1 interactions helps identify compounds that may alleviate opioid-induced constipation. Our service employs advanced assays—[3H]-DPDPE displacement, [35S]-GTPγS binding, fluorescent and saturation binding, competitive binding, and several radioligand displacement tests—measuring critical pharmacological parameters such as IC₅₀, EC₅₀, Ki, pKi, ED₅₀, pA₂, pKb, and Kb for robust drug candidate evaluation.

Opioid Receptor Mu 1

The Opioid Receptor Mu 1 (MOR-1) plays a key role in opioid-induced constipation by mediating gut motility inhibition. Testing MOR-1 is crucial for developing constipation therapies that minimize opioid side effects. We employ advanced methods such as arrestin recruitment assays, radioligand displacement, BRET/FRET, binding assays, and animal models (e.g., fecal pellet output, charcoal meal test). Key parameters measured include EC-50, IC-50, Ki, Kd, and ED-50 to assess drug efficacy and receptor binding affinity.

Opioid Related Nociceptin Receptor 1

The Opioid Related Nociceptin Receptor 1 (NOP) is implicated in gastrointestinal motility and plays a key role in opioid-induced constipation. Testing NOP activity is crucial for developing targeted constipation therapies. Our service utilizes advanced assays—including arrestin recruitment, displacement of radiolabeled ligands ([3H]-nociceptin, [3H]-UFP-101), [35S]-GTPγS binding, fluorescent, and FRET assays—measuring critical pharmacological parameters such as IC50, pA2, Ki, EC50, and pKi.

Relaxin Family Peptide/Insl5 Receptor 4

The Relaxin Family Peptide/Insl5 Receptor 4 (RXFP4) plays a crucial role in regulating gastrointestinal motility, making it a promising target for constipation drug development. Our testing service evaluates compound activity at RXFP4 using cAMP accumulation, arrestin recruitment, europium-DTPA-relaxin-3/INSL5 displacement, and nano-luciferase assays. Key pharmacological parameters measured include pKi and pEC50, providing critical data for candidate selection and optimization.

Solute Carrier Family 10 Member 2

Solute Carrier Family 10 Member 2 (SLC10A2) regulates bile acid reabsorption, influencing intestinal fluid balance and motility, making it a key target in constipation drug development. Testing SLC10A2 activity via taurocholate uptake assays is essential to assess drug efficacy and safety. The primary parameter measured is IC50, indicating the concentration at which a compound inhibits 50% of SLC10A2 function, guiding candidate selection and optimization.